News + Press

Explore by Category
Select
Press Release
Interius BioTherapeutics Receives HREC Approval and CTN Clearance from the TGA to Commence a Phase 1 Clinical Trial for Its First-in-Class In Vivo CAR Therapeutic for B Cell Malignancies
July 09, 2024

PHILADELPHIA, July 9, 2024 /PRNewswire/ — Interius BioTherapeutics, a leading developer of in vivo cell-specific gene medicines, today announced that…

read more
Press Release
Interius BioTherapeutics Receives HREC Approval and CTN Clearance from the TGA to Commence a Phase 1 Clinical Trial for Its First-in-Class In Vivo CAR Therapeutic for B Cell Malignancies
July 09, 2024

PHILADELPHIA, July 9, 2024 /PRNewswire/ — Interius BioTherapeutics, a leading developer of in vivo cell-specific gene medicines, today announced that…

read more
Abstracts & Publications
Targeted in vivo Generation of CAR T and NK Cells Utilizing an Engineered Lentiviral Vector Platform
June 22, 2023

  Download the poster here.

read more
Press Release
Interius BioTherapeutics Highlights Strong Preclinical Data Supporting In Vivo Chimeric Antigen Receptor (CAR) Vector Evaluation in Clinic
June 21, 2023

PHILADELPHIA, June 21, 2023 /PRNewswire/ — Interius BioTherapeutics, a leading developer of in vivo cell-specific genetic medicine therapeutics, today announced…

read more
Press Release
Interius BioTherapeutics Announces Successful Manufacturing Partnership with WuXi Advanced Therapies
May 09, 2023

PHILADELPHIA, May 9, 2023 /PRNewswire/ — Interius BioTherapeutics, a preclinical stage gene therapy company developing novel methods for…

read more
Press Release
Interius BioTherapeutics Hosts Immersive, Hands-on Event to Ignite Students’ Passion for Science
April 27, 2023

Philadelphia, PA – April 27, 2023 – Interius BioTherapeutics, a preclinical stage gene therapy company…

read more
Media Coverage
Nature Magazine Coverage: Ensoma and Interius BioTherapeutics: in vivo veritas
August 26, 2022

An innovation showcase of protein degraders, RNA therapeutics, delivery vectors and gene modifiers

read more
Press Release
Interius Bio Announces Granting of US Patent to Support in Vivo Cell-Specific Gene Delivery Platform
December 09, 2021

Company also celebrates “Deal of the Year” awarded by The Penn Center for Innovation PHILADELPHIA,…

read more
Press Release
Pennovation Lab Welcomes New Tenant Interius BioTherapeutics to Its Innovation Ecosystem
October 05, 2021
read more
Media Coverage
Biocentury: Interius Design: Penn Spinout Gets Specific with In Vivo CAR Ts
June 07, 2021
read more
Press Release
Interius BioTherapeutics Raises $76M Series A Financing to Advance Breakthrough Cell and Gene Therapy Platform
May 18, 2021

Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, today announced that it has raised $76 million in an oversubscribed Series A financing.

read more